TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation

Kenichiro Kobayashi, Naoyuki Miyagawa, Kazumasa Mitsui, Masaki Matsuoka, Yasuko Kojima, Hiroyuki Takahashi, Kaori Ootsubo, Junichi Nagai, Hitomi Ueno, Takeshi Ishibashi, Sara Sultana, Yoko Okada, Shingo Akimoto, Hajime Okita, Kimikazu Matsumoto, Hiroaki Goto, Nobutaka Kiyokawa, Akira Ohara

研究成果: Article査読

45 被引用数 (Scopus)

抄録

We report a 10-year-old male with relapsing Ph-like acute lymphoblastic leukemia (ALL) bearing ATF7IP/PDGFRB translocation. He was refractory to conventional therapy, and was finally treated with single-agent second-generation TKI dasatinib. The therapeutic response was prompt, with the disappearance of minimum residual disease (MRD) based on genomic PCR analysis within 3 months, and he has maintained complete molecular remission for 12 months. This case report describes an early-phase response to TKI monotherapy on Ph-like ALL, and technical tips for MRD monitoring on long-term follow-up.

本文言語English
ページ(範囲)1058-1060
ページ数3
ジャーナルPediatric Blood and Cancer
62
6
DOI
出版ステータスPublished - 2015 6 1
外部発表はい

ASJC Scopus subject areas

  • 小児科学、周産期医学および子どもの健康
  • 血液学
  • 腫瘍学

フィンガープリント

「TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル